Cancer Resource--Pathology, Registry and Biorepositories

描述（由申请人提供）： 技术和科学知识的迅速发展为人类 转化研究中的重要发现的机会。作为 因此，将组织特征与 患者的人口统计学、病理学和临床记录， 损害病人的权利和医疗记录的保密性。这 全面的研究方法将使研究取得重大进展， 从不同学科研究癌症病因、进展和预后 西奈山医疗中心本建议的总体目标是 建立进行癌症研究的基础设施， 标本癌症资源：病理学、登记和生物储存库 本文将建立在我们现有的结肠癌和乳腺癌基础设施上， 家族登记、肿瘤登记和标本库。巨蟹座的目标 资源将促进从基础科学到转化科学的研究 研究和大规模分子流行病学研究。具体地说， 目的是：1）获得接受手术的患者的术前同意， 手术治疗偶发或疑似癌症（从乳腺和结肠开始 癌症）为DHRCC数据和生物储存库做出贡献; 2）建立一个 包含知情同意患者信息的综合数据库， 病理、临床和流行病学数据。后续行动情况，执行人 肿瘤登记处，也将包括在这个数据库; 3）建立一个 含有来自癌症和高风险的库存血清、血浆和DNA的生物储存库， 风险患者和健康对照供研究者使用，并提出建议 经咨询委员会批准，详细的临床，病理和 人口流行病学数据。存储库服务（血液 处理、等分和储存）将可用于样本库， 研究人员与资助的研究; 4）建立一个组织库， 患者记录，新鲜采集和石蜡包埋标本， 并提供组织学服务（切片、免疫组织化学染色 和激光捕获显微切割）。一个 将成立咨询委员会，以监督数据的运行， 生物储存库，并征求和审查科学质量的建议 计划使用组织和血液样本此共享资源将 促进正在进行的和未来的研究有关的癌症病因学，标志物 癌症进展和癌症诊断后的预后。的可用性 关于患者特征的数据将是一个宝贵的资源， 使用肿瘤和正常组织以及其他生物样本进行转化研究。

DESCRIPTION (provided by applicant): Rapid advances in technology and scientific knowledge have opened new opportunities for important discoveries in translational research. As a result, it is becoming increasingly important to link tissue characteristics of patients to demographic, pathologic and clinical records, without compromising patients' rights and confidentiality of medical records. This comprehensive approach to research would allow for significant progress in the study of cancer etiology, progression and prognosis from various disciplines at Mount Sinai Medical Center. The overall aim of this proposal is to establish the infrastructure for conducting cancer research with human specimens. The "Cancer Resource: Pathology, Registry, and Biorepository" herein will build upon our existing infrastructure of colon and breast cancer familial registries, Tumor Registry and specimen banks. The aims of the Cancer Resource will facilitate research ranging from basic science to translational research, and to large-scale molecular epidemiologic studies. Specifically, the objectives are: 1) to obtain presurgical consent from patients undergoing surgery for incident or suspected cancer (beginning with breast and colon cancer) to contribute to the DHRCC Data and Biorepository; 2) to establish a comprehensive database with information from consented patients related to pathologic, clinical and epidemiologic data. Follow-up status, conducted by the Tumor Registry, will also be included in this database; 3) to establish a biorepository containing banked serum, plasma and DNA from cancer and high- risk patients and healthy controls for use by investigators with proposals approved by the Advisory Committee, with detailed clinical, pathologic and epidemiologic data available on that population. Repository services (blood processing, aliquoting and storage) will be available for specimen banking for investigators with funded studies; 4) to establish a tissue repository, linked to patient records, with freshly harvested and paraffin-embedded specimens, and to provide histology services (sectioning, immunohistochemical staining and laser capture microdissection) at a reduced cost to cancer researchers. An Advisory Committee will be established to oversee the running of the Data and Biorepositories, and solicit and review the scientific quality of proposals planning to use tissue and blood specimens. This Shared Resource will facilitate ongoing and future studies related to cancer etiology, markers of cancer progression, and prognosis after cancer diagnosis. The availability of data on patient characteristics will be an invaluable resource for translational research using tumor and normal tissue and other biospecimens.